Compare NBHC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBHC | HROW |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2012 | N/A |
| Metric | NBHC | HROW |
|---|---|---|
| Price | $37.95 | $49.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $44.33 | ★ $68.86 |
| AVG Volume (30 Days) | 313.4K | ★ 550.3K |
| Earning Date | 01-21-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.15 | N/A |
| Revenue | ★ $405,867,000.00 | $250,042,000.00 |
| Revenue This Year | $8.48 | $38.96 |
| Revenue Next Year | $28.10 | $43.38 |
| P/E Ratio | $12.03 | ★ N/A |
| Revenue Growth | 1.03 | ★ 47.83 |
| 52 Week Low | $32.83 | $20.85 |
| 52 Week High | $44.93 | $51.53 |
| Indicator | NBHC | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 60.49 |
| Support Level | $39.35 | $44.19 |
| Resistance Level | $40.68 | $51.53 |
| Average True Range (ATR) | 0.61 | 2.32 |
| MACD | -0.29 | -0.04 |
| Stochastic Oscillator | 8.36 | 71.25 |
National Bank Holdings Corp is a bank holding company. It provides various banking products and financial services to commercial, business, and consumer clients in the United States. The company offers deposit products including checking accounts, savings accounts, money market accounts, and other deposit accounts, including fixed-rate and fixed-maturity time deposits. It also provides commercial and industrial loans and leases. In addition, it offers treasury management solutions comprising online and mobile banking, commercial credit cards, wire transfers, automated clearing house, and electronic bill payments.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.